Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Join | Sign in
Home>Videos>This Video
  Videos

Return

Tumour Regression after Intravenous Administration of Novel Tumour-targeted Nanomedicines
SELECTBIO

The possibility of using genes as medicines to treat cancer is limited by the lack of safe and efficacious delivery systems able to deliver therapeutic genes selectively to tumours by intravenous administration, without secondary effects to healthy tissues. In order to remediate to this problem, we investigated if the conjugation of the polypropylenimine dendrimer to transferrin, whose receptors are overexpressed on numerous cancers, could result in a selective gene delivery to tumours after intravenous administration, leading to an increased therapeutic efficacy. The objectives of this study are to evaluate the targeting and therapeutic efficacies of a novel transferrin-bearing polypropylenimine dendrimer. The intravenous administration of transferrin-bearing polypropylenimine polyplex resulted in gene expression mainly in the tumours. Consequently, the intravenous administration of the delivery system complexed to a therapeutic DNA encoding TNF led to a rapid and sustained tumour regression over one month (90% complete response, 10% partial response on A431 human epidermoid tumours). It also resulted in tumour suppression for 60% of PC-3 and 50% of DU145 prostate tumours. The treatment was well tolerated by the animals, with no apparent signs of toxicity. Transferrin-bearing polypropylenimine is therefore a highly promising delivery system for cancer therapy

Request more information
Company product page


Access to this article and other content is for registered users.

Join the Technology Networks Community

  • Access to the latest scientific news, products and research through Technology Networks
  • Upload and share your posters on ePosters
  • View a library of 1,800+ scientific and medical posters
  • A library of 3,000+ scientific videos on LabTube


Sign In



Forgotten your details? Click Here
If you already have an account with Technology Networks, please use your existing login details. If you do not yet have an account please join here.

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Label-Free Binding Analysis Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
Vitamin E Keeps Muscles Healthy
Body builders have it right: vitamin E does help build strong muscles, and scientists appear to have figured out one important way it does it.
Microchip Captures Clusters of Circulating Tumor Cells
Researchers have developed a microfluidic chip that can capture rare clusters of circulating tumor cells, which could yield important new insights into how cancer spreads.
New Method For Measuring The Concentration Of Medicines In The Blood
Researchers at EPFL have come up with a quick and portable new device for measuring the amount of medicinal drugs in blood.
Alternate Administration Routes for Psychotropic Drugs Reviewed
A review in the Annals of Pharmacotherapy has examined the literature on alternative routes of administration for antipsychotic and antidepressant medications.
Promising Results of Phase 1/2 Trial of Rociletinib in EGFR Lung Cancer Published
Results have been published of a multi-center phase I/II study of the investigational anti-cancer agent rociletinib in patients with EGFR-mutant non-small cell lung cancer (NSCLC) that had progressed after previous treatment with EGFR inhibitors.
Epilepsy Drug Metabolism Test Launched for Epilepsy and Seizure Disorders
Courtagen Life Sciences, Inc have announced the release of a NGS test focused on detection of anti-epileptic drug (AED) compatibilities and interactions for patients receiving treatment for epilepsy or other seizure disorders.
Supercooling May Aid Drug Delivery
A new study published is the first to break down the rules governing the complex process of crystallization through rapid-cooling.
Quotient Clinical Completes Innovative First-In-Human Program
First-in-human clinical program designed to develop an optimal oral formulation.
Neuropsychiatric Drug Candidate Shows Good Safety & Tolerability
Transition Therapeutics announces results from Phase 1 AME & renal clearance clinical studies of neuropsychiatric drug candidate ELND005.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters